



# 2013 European guideline for the management of balanoposthitis

SK Edwards<sup>1</sup>, CB Bunker<sup>2</sup>, Fabian Ziller<sup>3</sup> and Willem I van der Meijden<sup>4</sup>

## Abstract

Balanoposthitis can be caused by a disparate range of conditions affecting the penile skin. This guideline concentrates on a selected group of conditions and offers recommendations on the diagnostic tests and treatment regimens needed for the effective management of balanoposthitis.

## Keywords

Balanitis, balanoposthitis, lichen sclerosus, Zoon's, lichen planus, candida, anaerobic, aerobic, psoriasis, circinate, eczema, erythroplasia of Queyrat, Bowen's disease, Bowenoid papulosis, penile dermatoses, sexual health, men

Date received: 29 January 2014; accepted: 16 March 2014

## Introduction

The main objective of this guideline is to aid recognition of the symptoms and signs and complications of penile skin conditions that may present to a variety of clinical specialists in Europe, including dermatology, sexual health or urology. This guideline concentrates on a selected group of conditions, which may be managed by clinicians practising in these disciplines, either alone or in conjunction with other specialists. It is not intended as a comprehensive review of the treatment of all forms of balanitis. It is aimed primarily at people aged 16 years or older.

This guideline offers recommendations on the diagnostic tests and treatment regimens needed for the effective management of balanoposthitis and includes the following penile conditions:

Candidal balanitis  
Anaerobic balanitis  
Aerobic balanitis  
Lichen sclerosus  
Lichen planus  
Zoon's (plasma cell) balanitis  
Psoriasis and circinate balanitis  
Eczema (including irritant, allergic and seborrhoeic)  
Non-specific balanoposthitis  
Fixed drug eruptions

Premalignant conditions:

Erythroplasia of Queyrat  
Bowen's disease  
Bowenoid papulosis

## Aetiologies

Balanitis describes inflammation of the glans penis; posthitis is inflammation of the prepuce. In practice both areas are often affected and the term balanoposthitis is then used. It is a collection of disparate conditions with similar clinical presentation and varying aetiologies affecting a particular anatomical site (see Table 1). Balanitis is uncommon in circumcised men

<sup>1</sup>Department of Genitourinary Medicine, Cambridgeshire Community Services, Bury St Edmunds, UK

<sup>2</sup>Department of Dermatology, University College Hospital, London, UK

<sup>3</sup>Department of Dermatology, DRK Hospital Chemnitz-Rabenstein, Chemnitz, Germany

<sup>4</sup>Department of Dermatology, Havenziekenhuis, Rotterdam, The Netherlands

**Lead editor for IUSTI:** Willem I van der Meijden

### Corresponding author:

SK Edwards, Department of Genitourinary Medicine, Cambridgeshire Community Services, Bury St Edmunds, UK.  
Email: sarah.edwards6@nhs.net



NICE has accredited the process used by BASHH to produce its European guideline on the management of balanoposthitis. Accreditation is valid for 5 years from 2014. More information on accreditation can be viewed at [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation)

**Table 1.** Conditions affecting the glans and prepuce<sup>1</sup>.

Infectious	Inflammatory dermatoses	Premalignant (penile carcinoma in situ)
<i>Candida albicans</i>	Lichen sclerosus	Bowen's disease
Streptococci	Lichen planus	Bowenoid papulosis
Anaerobes	Psoriasis and circinate balanitis	Erythroplasia of Queyrat
Staphylococci	Zoon's balanitis	
<i>Trichomonas vaginalis</i>	Eczema (including irritant, allergic and seborrhoeic)	
Herpes simplex virus	Allergic reactions (including fixed drug eruption and Stevens Johnson Syndrome)	
Human papillomavirus		
<i>Mycoplasma genitalium</i>		

and in many cases preputial dysfunction is a causal or contributing factor.

Other, rarer dermatoses are not included in this table. Infections, especially with candida, may be secondary to primary inflammatory dermatoses.

## General management of the patient with balanitis<sup>2</sup>

### Clinical features

- Symptoms and signs vary according to aetiology and specific conditions are covered in more detail individually.
- Descriptions of the typical appearances of certain balanitides are given separately in the management section.

### Diagnosis

- Balanitis is a descriptive term covering a variety of unrelated conditions, the appearances of which may be suggestive but should never be thought to be pathognomonic and biopsy<sup>3</sup> is sometimes needed to exclude pre-malignant disease.
- The following investigations are intended to aid diagnosis in cases of uncertainty:
  - Sexual history taken, with specific questioning on sexual risk taking.
  - Sub-preputial swab for *Candida spp* and bacterial culture – should be undertaken in most cases to exclude an infective cause or superinfection of a skin lesion or dermatosis.
  - Urinalysis for glucose – appropriate in some cases but especially if candidal infection is suspected.
  - Herpes simplex virus (HSV) nucleic acid amplification test or culture for HSV – if ulceration present.
  - Dark ground examination for spirochaetes and/or *Treponema pallidum* (TP) nucleic acid

amplification test (where available) – if an ulcer is present, or alternatively syphilis serology with follow-up at 3 months.

- Culture/wet prep or nucleic acid amplification test for *Trichomonas vaginalis* – particularly if a female partner has an undiagnosed vaginal discharge.
- Full routine screening for other sexually transmitted infections (STIs) – particularly screening for *Chlamydia trachomatis* infection/non-specific urethritis if a circinate-type balanitis is present.
- Dermatology opinion for dermatoses and suspected allergy.
- Biopsy – if the diagnosis is uncertain and the condition persists<sup>3,4</sup>

### Management

The aims of management are to minimise sexual dysfunction, to minimise urinary dysfunction, to exclude penile cancer, to treat pre-malignant disease and to diagnose and treat STIs. Predisposing factors include both poor hygiene and overwashing, over-the-counter (OTC) medications as well as non-retraction of the foreskin.

Many cases of balanitis seen in practice are a simple intertrigo; i.e. inflammation between two layers of skin with bacterial or fungal overgrowth. Rapid resolution can be achieved most frequently in practice by advising the patient to keep his foreskin retracted if possible, having advised him of the risk of paraphimosis. Saline baths are also useful, and medicated OTC talcum powders are helpful in drying the area. This advice is simple, but compliance may be challenging.

Many patients will present having tried antifungal creams, often obtained OTC. The experience is of relapse with these agents, and the simple measures have a more durable effect when compliance is lasting.

### General advice

- Avoid soaps while inflammation is present<sup>5</sup>
- Advise about risks of condom failure if creams are being applied
- Patients should be given a detailed explanation of their condition with particular emphasis on any implications for their health (and that of their partner where a sexually transmissible agent is found).

### Management of specific balanitides

#### Infective balanitides

A range of infective agents have been isolated more frequently in men with balanoposthitis, and may not be easily differentiated by clinical findings.<sup>6</sup> Agents include *Candida spp*, *Staphylococcus spp*,<sup>7</sup> *Streptococcus spp*<sup>8,9</sup> and more recently *Mycoplasma genitalium*.<sup>10</sup>

#### Candidal balanitis (less than 20% of cases of balanoposthitis)

##### Clinical features

- Symptoms: erythematous rash with soreness and/or itch
- Appearance: blotchy erythema with small papules which may be eroded, or dry dull red areas with a glazed appearance.
- Older age has also been identified as a risk factor.<sup>11</sup>

##### Diagnosis

- Sub-preputial culture (n.b. isolation of candida on culture does not prove causality, as it may represent colonisation of other underlying dermatoses)
- Consider urinalysis for glucose.
- Investigation for other causes e.g. HIV or other causes of immunosuppression if balanitis is severe or persistent.
- Many dermatologists believe that this primary diagnosis is very rare (apart from in diabetes mellitus [DM] and even in HIV) and that candida is almost always an opportunistic pathogen, signifying an underlying dermatosis.

### Management

#### Recommended regimens

- Clotrimazole cream 1%<sup>12</sup> (Ib, A).
- Miconazole cream 2%<sup>13</sup> (IIa, B).

Apply twice daily until symptoms have settled.

#### Alternative regimens

- Fluconazole 150 mg stat orally<sup>12</sup> (Ib, A) – if symptoms severe.
- Nystatin cream<sup>13</sup> 100,000 units/g – if resistance suspected, or allergy to imidazoles (IIa, B).
- Topical imidazole with 1% hydrocortisone – if marked inflammation is present (IV, C).
- Although there has been an increase in reports of drug resistance in serious candidal infection, there is no new evidence pertaining to treatment of candidal balanitis.

**Sexual partners.** As there is a high rate of candidal infection in sexual partners, they should be offered testing for candida or empiric anti-candidal treatment to reduce the reservoir of infection in the couple.

#### Follow-up

Not required unless symptoms and signs are particularly severe or an underlying problem is suspected.

### Anaerobic infection<sup>14</sup>

#### Clinical features

- Symptoms: foul smelling sub preputial inflammation and discharge, in severe cases associated with swelling and inflamed inguinal lymph nodes.
- Appearance: preputial oedema, superficial erosions; milder forms also occur.

#### Diagnosis

- Gram stain may show Fusiform/mixed bacterial picture.
- Sub-preputial culture (to exclude other causes e.g. *Trichomonas vaginalis*).
- *Gardnerella vaginalis* is a facultative anaerobe which may be isolated.
- Swab for HSV infection if ulcerated.

### Management

Advice about genital hygiene.

#### Recommended regimen

- Metronidazole 400–500 mg twice daily × 1 week (IV, C). The optimum dosage schedule for treatment is unknown.
- Milder cases may respond to topical metronidazole.

### Alternative regimen

- Co-amoxiclav 375 mg three times daily × 1 week.
- Clindamycin cream applied twice daily until resolved.

These treatments have not been assessed in clinical trials (IV, C).

## Aerobic infection

### Clinical features

- Variable inflammatory changes including uniform erythema ± oedema.

### Diagnosis

- Sub-preputial culture
- *Streptococci spp* and *Staphylococcus aureus* have both been reported as causing balanitis. Other organisms may also be involved.

### Management

- Treatment is usually topical. Severe cases may require systemic antibiotics.

### Recommended regimens (IV, C)

- Trimovate cream applied once daily
- Erythromycin 500 mg qds × 1 week
- Co-amoxiclav 375 mg three times daily × 1 week

### Alternative regimens

- Depends on the sensitivities of the organism isolated. Treatment is usually topical. Severe cases may require systemic antibiotics while awaiting culture results.

## Sexually transmitted infections

Balanoposthitis has been described with

<ul style="list-style-type: none"> <li>● Herpes simplex virus</li> <li>● <i>Trichomonas vaginalis</i></li> <li>● Syphilis<sup>15</sup></li> </ul>	} Diagnosis and treatment as per specific guidelines
---------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------

## Lichen sclerosus<sup>4,16</sup>

### Aetiology

An inflammatory scarring skin condition, possibly of autoimmune pathogenesis, but may be due to chronic occluded contact with urine in the uncircumcised. The condition occurs in all ages. It is probably responsible for many cases of phimosis in childhood.<sup>4</sup>

### Clinical features<sup>4,17</sup>

#### Symptoms

- Itching, soreness, splitting, haemorrhagic blisters, dyspareunia, problems with urination.
- May be asymptomatic.

#### Signs

- Typical appearance: white patches on the glans, often with involvement of the prepuce. There may be haemorrhagic vesicles, purpura and rarely blisters and ulceration. Architectural changes include blunting of the coronal sulcus, phimosis or wasting of the prepuce, and meatal thickening and narrowing.

### Complications

- Phimosis
- Urethral stenosis
- Malignant transformation to squamous cell carcinoma. The risk has been quoted as a high as 10%.<sup>4</sup> In established penile cancer the association with lichen sclerosus is thought to be about 50% (the other 50% being associated with HPV).<sup>18</sup>
- Extra-genital disease can occur. In contrast with females perianal disease is uncommon.

### Diagnosis

- Typical clinical features
- Biopsy: This initially shows a thickened epidermis which then becomes atrophic with follicular hyperkeratosis. This overlies a band of dermal hyalinisation with loss of the elastin fibres, with an underlying perivascular lymphocytic infiltrate. Biopsy should only be carried out by experienced practitioners. A negative biopsy does not exclude lichen sclerosus, and a positive biopsy does not exclude squamous cell carcinoma or carcinoma in situ elsewhere. The choice of the area biopsied is important both in terms of the risks and in getting an adequately

representative sample. Histological interpretation can be difficult and needs clinico-pathological correlation.

## Management<sup>16,19</sup>

### Recommended regimens

- Ultrapotent topical steroids<sup>16,20,21</sup> (e.g. clobetasol propionate) applied once daily until remission, then gradually reduced. Intermittent use (e.g. once weekly) may be required to maintain remission. A double-blind study in children showed response to topical mometasone furoate, particularly in early cases without scarring.<sup>22</sup> (Ia, A)
- In view of the immunosuppressive effects of potent steroids, patients with a history of genital warts should be warned about the risk of a relapse; consider prophylactic aciclovir in patients with a history of genital HSV infection.
- Secondary infection should be treated.

### Alternative regimens

- Although topical calcineurin inhibitors have been claimed to be efficacious<sup>20,23</sup> (pimecrolimus applied twice daily, Ib, A), there is concern about the risk of malignancy.<sup>24</sup>
- Surgery may be indicated to address symptoms due to persistent phimosis or meatal stenosis (III, B). This may include circumcision,<sup>25,26</sup> meatotomy or urethroplasty.
- Circumcision is indicated for failed topical medical treatment.

### Follow-up

- Patients with a persistent requirement for topical treatment should be circumcised.
- Patients with atypical or persistent lesions should receive more specialist input.<sup>27</sup>
- Patients should be advised to contact the general practitioner or clinic if the appearances change (IV, C).

## Lichen planus<sup>4</sup>

### Aetiology

Lichen planus is an inflammatory disorder with manifestations on the skin, genital and oral mucous membranes. More rarely it affects the conjunctiva and

oesophagus. It is an inflammatory condition of unknown pathogenesis, but it is thought to have an immunological basis.

### Clinical features

- Symptoms: Change in appearance, more rarely itch and soreness/dyspareunia.
- Clinical appearance: Purplish well-demarcated plaques (can be on glans and prepuce and on the shaft of the penis); alternatively erosive lesions on the mucosal surfaces.
- Natural history: Mucosal lichen planus is a chronic condition with remissions and exacerbations, in contrast to cutaneous lichen planus which tends to resolve spontaneously after 12–18 months.

### Diagnosis

- Clinical features of purplish lesions, or supporting evidence of lichen planus lesions elsewhere on the body. This particularly includes the mouth in cases of erosive (penogingival) disease.
- Biopsy: irregular saw-toothed acanthosis, increased granular layer and basal cell liquefaction. Band-like dermal infiltrate (mainly lymphocytic). The condition may be associated with pre-cancerous change.<sup>27</sup>

## Management<sup>4,28</sup>

### Recommended regimen

- Moderate to ultrapotent topical steroids depending on severity (for both mucosal and cutaneous disease) (III, B).

### Alternative regimens

- Topical and oral ciclosporin have been used for erosive disease<sup>29,30</sup> (IV, C).
- Topical calcineurin inhibitors have also been tried in lichen planus of the vulval and oral mucosa (pimecrolimus applied twice daily, Ib A),<sup>31</sup> but no specific reports in penile disease (noting the caution as for lichen sclerosus) (IV, C).
- Circumcision: May be the treatment of choice for some cases of erosive lichen planus<sup>32</sup> (IV, C).

### Follow-up

- Patients with a persistent requirement for topical treatment should be circumcised.

- Atypical or persistent disease should receive more specialist input.
- Patients should be advised to contact the general practitioner or clinic if the appearances change (IV, C).

## Zoon's (plasma cell) balanitis<sup>4</sup>

### Aetiology

Zoon's balanitis is a disease of older men who are uncircumcised. It is thought to be due to irritation, partially caused by urine, in the context of a 'dysfunctional prepuce.' It is generally regarded as a benign condition. Zoonoid inflammation clinically and histologically very frequently complicates other dermatoses, including pre-cancer and cancer.

### Clinical features

- Symptoms: Change in appearance. Rarely blood-stained discharge. Rarely dyspareunia.
- Clinical appearance: Includes well-circumscribed orange-red glazed areas on the glans and the inside of the foreskin, with multiple pinpoint redder spots – 'cayenne pepper spots.' These are in a symmetrical distribution.

### Diagnosis

- Clinical features of symmetrical, well-marginated, erythema of the glans and foreskin; however, clinical distinction from other inflammatory and pre-malignant conditions is difficult and a high index of suspicion is recommended.
- Biopsy: early cases show epidermal thickening but this is followed by epidermal atrophy, at times with erosions. There is epidermal oedema (often mild) and a predominantly plasma cell infiltrate in the dermis with haemosiderin deposition and extravasated red blood cells.<sup>33</sup> Caveat: Zoonoid inflammation complicates other dermatoses and 'positive' biopsy findings do not confirm the diagnosis or exclude neoplasia.

## Management<sup>4</sup>

### Recommended regimens

- Circumcision – this has been reported to lead to the resolution of lesions<sup>34</sup> (IV, C).
- Topical steroid preparations – with or without added antibacterial agents e.g. Trimovate cream, applied once or twice daily<sup>35</sup> (IV, C).
- Hygiene measures.

### Alternative treatments

- CO<sub>2</sub> laser – this has been used to treat individual lesions<sup>36</sup> (IV, C).
- Although topical tacrolimus has been reported in the treatment of Zoon's balanitis<sup>37</sup> (IV, C), there is controversy about the risk of malignancy with the use of topical calcineurin inhibitors.<sup>38</sup>

### Follow-up

- Dependent on clinical course and treatment used, especially if topical steroids are being used long-term.
- Penile biopsy should be performed if features are atypical or do not resolve with treatment. It should be remembered that there are cases where even biopsies failed to identify pre-malignant disease.<sup>33</sup>

## Psoriasis<sup>4,39</sup>

### Clinical features

- Symptoms: Change in appearance, soreness or itching.
- Appearance: In the circumcised male psoriasis on the glans is similar to the appearance of the condition elsewhere, with red scaly plaques. In the uncircumcised scaling is lost and the patches appear red and glazed.

### Diagnosis

- Is supported by evidence of psoriasis elsewhere.
- Biopsy may be necessary, particularly in the glazed pattern of psoriasis which can look similar to pre-malignant conditions and other inflammatory conditions. The typical histological appearances include parakeratosis and acanthosis with elongation of rete ridges. There are collections of neutrophils in the epidermis. Maceration and secondary infection can modify appearances.

## Management

### Recommended regimen

- Moderate potency topical steroids<sup>40</sup> (± antibiotic and antifungal) (IV, C).
- Emollients



### Alternative regimens

- Topical Vitamin D preparations (calcipotriol or calcitriol applied twice daily)<sup>41</sup> (IV,C).
- Topical bethamethasone dipropionate/calcipotriol ointment may be well tolerated in treatment of anogenital psoriasis, but potent steroids may not be indicated<sup>40</sup> (IV,C).
- Topical tacrolimus has been used in small studies<sup>42</sup> but should not be used as first-line therapy (IV, C). Topical pimecrolimus can also be useful.

## Circinate balanitis<sup>4</sup>

### Aetiology

This characteristic presentation may occur in isolation or be seen in Reiter's disease – a post-infective syndrome, triggered by urethritis or enteritis in genetically predisposed individuals. It consists of skin problems, joint problems and ocular problems, with other systems affected more rarely. There is overlap with psoriasis in some cases. It has been reported in association with HIV infection.

### Clinical features

#### Signs

- Typical appearance: greyish white areas on the glans which coalesce to form 'geographical' areas with a white margin. It may be associated with other features of Reiter's syndrome but can occur without.

### Diagnosis

- On clinical appearance in association with other features of Reiter's syndrome.
- Biopsy: spongiform pustules in the upper epidermis, similar to pustular psoriasis.

### Management

#### Further investigation

- Screening for STIs. Syphilis can also give rise to similar features.<sup>15</sup>
- Consider testing for HLAB27. A positive test can confirm a diagnosis and provide important information about the risk of associated disease, such as urethritis, gastrointestinal disease and arthritis.

#### Recommended regimen

- See under 'Psoriasis'
- Treatment of any underlying infection

### Sexual partners

- If an STI is diagnosed, the partner(s) should be treated as per the appropriate protocol.

### Follow-up

- May be needed for persistent symptomatic lesions.
- Associated STIs should be followed up as per appropriate guidelines.

## Eczema<sup>4</sup>

### Irritant/allergic balanitides

**Aetiology.** Symptoms can be associated with irritants, such as more frequent genital washing with soap, a history of atopy or exposure to topical agents suggesting delayed hypersensitivity. In a very small number of cases, a history of a precipitant may be obtained.

#### Clinical features

- Appearance: ranges from mild non-specific erythema to widespread oedema of the penis.

#### Diagnosis

- Patch tests: referral to a dermatologist is useful if allergy is suspected.
- Biopsy: eczematous with spongiosis and non-specific inflammation.
- Culture: to exclude superinfection.

### Management

#### General advice

- Avoidance of precipitants – especially soaps.<sup>5</sup>
- Emollients – applied as required and used as a soap substitute.<sup>5</sup>

#### Recommended regimen

- Hydrocortisone 1% applied once or twice daily until resolution of symptoms (IV, C).

#### Alternative regimen

- In more florid cases more potent topical steroids may be required and may need to be combined with antifungals and/or antibiotics.

### Follow-up

Not required, although recurrent problems are common and the patients need to be informed of this.

## Seborrhoeic dermatitis

### Aetiology

Hypersensitivity to *Pityrosporum ovale*.

### Clinical features

Mild itch or redness (less likely to have scaling at this site).

### Diagnosis

Supported by classical findings at other sites (nasolabial folds, scalp, ears, brows).

### Management

#### Recommended regimen

- Antifungal cream with a mild to moderate steroid.

#### Alternative regimens<sup>4</sup>

- Oral azole e.g. itraconazole (IV, C)
- Oral tetracycline (IV, C)
- Oral terbinafine may be effective<sup>43</sup>(Ib, A)

## Non-specific balanoposthitis<sup>4</sup>

### Aetiology

Unknown

### Clinical features

Chronic symptomatic presentation with relapses and remissions or persistence. No unifying diagnosis and poor response to a range of topical and oral treatments.

### Diagnosis

Failure to respond to maximal topical steroid and antifungal treatments (including potent steroids). Non-specific histology on biopsy. Non-specific histology at circumcision. No evidence of underlying infective cause (e.g. Chlamydia or mycoplasma).

### Management

Circumcision is curative.

## Fixed drug eruption

### Aetiology

- An uncommon condition, but the penis is one of the more commonly affected areas of the body. Precipitants include tetracyclines, salicylates, paracetamol, phenolphthalein and some hypnotics. Rarely a fixed drug eruption can occur when the sexual partner has taken the drug and it is assumed the toxic component of the drug is passed on through vaginal fluid.<sup>44</sup>

### Clinical features

Appearance: lesions are usually well demarcated and erythematous, but can be bullous with subsequent ulceration. As the inflammation settles the skin becomes brown.

### Diagnosis

- History: a drug history is essential.
- Rechallenge: This can confirm the diagnosis but can precipitate more severe reactions and should only be done with fully informed consent of the patient.
- Biopsy: Hydropic degeneration of the basal layer and epidermal detachment and necrosis with pigimentary incontinence.

### Management

- Condition will settle without treatment
- Topical steroids – e.g. mild to moderate strength twice daily until resolution<sup>45</sup> (IV, C).
- Rarely systemic steroids may be required if the lesions are severe.

### Follow-up

- Not required after resolution.
- Patients should be advised to avoid the precipitant.

## Pre-malignant conditions

There are three clinical presentations of penile carcinoma in situ (PCIS).<sup>46</sup> They are all strongly related to human papillomavirus infection<sup>47</sup> or lichen sclerosus. Erythroplasia of Queyrat and Bowen's disease are considered together as they are similar but affect the



non-keratinised and keratinised skin, respectively. All may progress to frank squamous cell carcinoma (SCC), but the risk is much less in Bowenoid papulosis, unless there is immunosuppression such as in HIV. SCC presents as an asymmetrical, irregular ulcer or nodule and may coexist with PCIS and lichen sclerosus.

### Clinical features<sup>48,49</sup>

#### *Erythroplasia of Queyrat (PCIS of the glans)*

- Typical appearance: red, velvety, well-circumscribed area on the glans. May have raised white areas, but if indurated suggests frank squamous cell carcinoma.

#### *Bowen's disease (PCIS of keratinised skin or shaft)*

- Typical appearance: Scaly, discrete, erythematous plaque.

### Diagnosis

- Biopsy: essential – shows squamous carcinoma in situ.

### Management

#### *Recommended regimen*

- Surgical excision - Local excision is usually adequate and effective<sup>49</sup> (III, B). Mohs' surgery can increase cure rates.

#### *Alternative regimens*

- Imiquimod 5% cream<sup>50,51</sup> (IV, C)
- Photodynamic therapy<sup>52</sup> (IV, C)
- Laser resection<sup>49</sup>
- Fluorouracil cream 5%<sup>53</sup> (IV, C)
- Cryotherapy<sup>54</sup> (IV, C)

### Follow-up

- Obligatory because of the likelihood of recurrence (5–10%), although optimum length of follow-up is uncertain.

### Bowenoid papulosis

- Typical appearance: Clinically very similar to genital warts. Lesions range from discrete papules to plaques that are often grouped and pigmented.

### Diagnosis

- Biopsy: the diagnosis should be confirmed by biopsy.

### Management<sup>4</sup>

#### *Recommended regimen*

- Imiquimod 5% cream<sup>50,51</sup> (IV, C)
- Laser resection<sup>49</sup>

#### *Alternative regimens*

- Photodynamic therapy<sup>52</sup> (IV, C)
- Fluorouracil cream 5%<sup>53</sup> (IV, C)
- Cryotherapy<sup>54</sup> (IV, C)
- Curettage and cautery
- Surgical excision – Local excision is usually adequate and effective<sup>49</sup> (III, B). Mohs' surgery can increase cure rates.

### Follow-up

- Obligatory because of the likelihood of recurrence (5–10%), although optimum length of follow-up is uncertain.

### Other skin conditions

A range of other skin conditions may affect the glans penis. These include erythema multiforme and immuno-bullous disorders, including pemphigus and dermatitis artefacta.<sup>55</sup>

A dermatologist's opinion should be sought for diagnosis and management of these conditions.

### Proposed review date

September 2018

### Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

### List of contributing organisations

IUSTI Europe  
European Academy of Dermatology and Venereology (EADV)  
European Dermatology Forum (EDF)

European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

Union of European Medical Specialists (UEMS)

European Centre for Disease Prevention and Control (ECDC)

European Office of the World Health Organisation (WHO-Europe)

## References

1. Edwards S and Bunker C. Other conditions affecting the male genitalia. In: Rogstad K (ed.) *ABC of sexually transmitted infections*, 6th ed. Oxford: Wiley-Blackwell, 2011, pp.35–41.
2. Edwards SK, Handfield-Jones S, on behalf of Clinical Effectiveness Group, British Association for Sexual Health and HIV. UK National Guideline on the Management of Balanoposthitis, <http://www.bashh.org/guidelines> (2008, accessed 19 January 2014).
3. Rao A and Bunker CB. Male genital skin biopsy. *Int J STD AIDS* 2011; 22: 418–419.
4. Bunker CB and Neill SA. The genital, perianal and umbilical regions. In: Burns T, Breathnach S, Cox N, et al. (eds) *Rook's textbook of dermatology*. Vol 71, 8th ed. New York: Wiley-Blackwell, 2010, pp.1–102.
5. Birley HDL, Walker MM, Luzzi GA, et al. Clinical features and management of recurrent balanitis: association with atopy and genital washing. *Genitourin Med* 1993; 69: 400–403.
6. Mallon E, Hawkins D, Dinneen M, et al. Circumcision and genital dermatoses. *Arch Dermatol* 2000; 136: 350–354.
7. Alsterholm M, Flytström I, Leifsdottir R, et al. Frequency of bacteria, Candida and malassezia species in balanoposthitis. *Acta Derm Venereol* 2008; 88: 331–336.
8. Lisboa C, Ferreira A, Resende C, et al. Infectious balanoposthitis: management, clinical and laboratory features. *Int J Dermatol* 2009; 48: 121–124.
9. Minami M, Wakimoto Y, Matsumoto M, et al. Characterization of *Streptococcus pyogenes* isolated from balanoposthitis patients presumably transmitted by penile-oral sexual intercourse. *Curr Microbiol* 2010; 61: 101–105.
10. Horner PJ and Taylor-Robinson D. Association of *Mycoplasma genitalium* with balanoposthitis in men with non-gonococcal urethritis. *Sex Transm Infect* 2011; 87: 38–40.
11. Lisboa C, Santos A, Dias C, et al. *Candidal balanitis*: risk factors. *J Eur Acad Dermatol Venereol* 2010; 24: 820–826.
12. Sary A, Soeltz-Szoets J, Ziegler C, et al. Comparison of the efficacy and safety of oral fluconazole and topical clotrimazole in patients with candidal balanitis. *Genitourin Med* 1996; 72: 98–102.
13. Forster GE and Harris JRW. Double blind therapeutic trial in balanitis – miconazole and nystatin. *Eur J Sex Transm Dis* 1986; 3: 81–83.
14. Ewart Cree G, Willis AT, Phillips KD, et al. Anaerobic balanoposthitis. *BMJ* 1982; 284: 859–860.
15. Kishimoto M, Lee MJ, Mor A, et al. Syphilis mimicking Reiter's syndrome in an HIV-positive patient. *Am J Med Sci* 2006; 332: 90–92.
16. Neill SM, Lewis FM, Tatnall FM, et al. British Association of Dermatologists' Guidelines for the Management of Lichen Sclerosus 2010. *Br J Dermatol* 2010; 163: 672–682.
17. Edmonds EVJ, Hunt S, Hawkins D, et al. Clinical parameters in male genital lichen sclerosus: a case series of 329 patients. *J Eur Acad Dermatol Venereol* 2012; 26: 730–737.
18. Pietrzak P, Hadway P, Corbishley CM, et al. Is the association between balanitis xerotica obliterans and penile carcinoma underestimated? *BJU Int* 2006; 98: 74–76.
19. Bunker CB. Comments on the BAD guidelines for the management of lichen sclerosus. *Br J Dermatol* 2011; 164: 894–895.
20. Chi CC, Kirtschig G, Baldo M, et al. Topical interventions for genital lichen sclerosus. *Cochrane Database Syst Rev* 2011; (2): CD008240.
21. Dahlman-Ghozlan K, Hedblad MA and von Krogh G. Penile lichen sclerosus et atrophicus treated with clobetasol dipropionate 0.05% cream: a retrospective clinical and histopathological study. *J Am Acad Dermatol* 1999; 40: 451–457.
22. Kiss A, Csontai A, Pirot L, et al. The response of balanitis xerotica obliterans to local steroid application compared with placebo in children. *J Urol* 2001; 165: 219–220.
23. Goldstein AT, Creasey A, Pfau R, et al. A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. *J Am Acad Dermatol* 2011; 64: e99–e104.
24. Bunker CB, Neill SM and Staughton RCD. Topical tacrolimus, genital lichen sclerosus and risk of squamous cell carcinoma. *Arch Dermatol* 2004; 140: 1169.
25. Liatsikos EN, Perimenis P, Dandinis K, et al. Lichen sclerosus et atrophicus. Findings after complete circumcision. *Scan J Urol Nephrol* 1997; 31: 453–456.
26. Kulkarni S, Barbagli G, Kirpekar D, et al. Lichen sclerosus of the male genitalia and urethra: surgical options and results in a multicenter international experience with 215 patients. *Eur Urol* 2009; 55: 945–954.
27. Porter WM, Francis N, Hawkins D, et al. Penile intraepithelial neoplasia: clinical spectrum and treatment of 35 cases. *Br J Dermatol* 2002; 147: 1159–1165.
28. Cheng S, Kirtschig G, Cooper S, et al. Interventions for erosive lichen planus affecting mucosal sites. *Cochrane Database Syst Rev* 2012; (2): CD008092.
29. Jemec GBE and Baadsgaard O. Effect of cyclosporin on genital psoriasis and lichen planus. *J Am Acad Dermatol* 1993; 29: 1048–1049.
30. Petrucci M, De Benedittis M, Pastore L, et al. Peno-gingival lichen planus. *J Periodontol* 2005; 76: 2293–2298.
31. Volz T, Caroli U, Lütke H, et al. Pimecrolimus cream 1% in erosive oral lichen planus—a prospective randomized double-blind vehicle-controlled study. *Br J Dermatol* 2008; 159: 936–941.

32. Porter WM, Dinneen M, Hawkins DA, et al. Erosive penile lichen planus responding to circumcision. *J Eur Acad Dermatol Venereol* 2001; 15: 266–268.
33. Weyers W, Ende Y, Schalla W, et al. Balanitis of Zoon: a clinicopathologic study of 45 cases. *Am J Dermatopathol* 2002; 24: 459–467.
34. Kumar B, Sharma R, Ragagopalan M, et al. Plasma cell balanitis: clinical and histological features – response to circumcision. *Genitourin Med* 1995; 71: 32–34.
35. Tang A, David N and Horton LW. Plasma cell balanitis of Zoon: response to Trimovate cream. *Int J STD AIDS* 2001; 12: 75–78.
36. Retamar RA, Kien MC and Chouela EN. Zoon's balanitis: presentation of 15 patients, 5 treated with a carbon dioxide laser. *Int J Dermatol* 2003; 42: 305–307.
37. Roe E, Dalmau J, Peramiquel L, et al. Plasma cell balanitis of zoon treated with topical tacrolimus 0.1%: report of three cases. *J Eur Acad Dermatol Venerol* 2007; 21: 284–285.
38. Thaçi D and Salgo R. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. *Clin Dermatol* 2010; 28: 52–56.
39. Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of *Psoriasis vulgaris* (short version). *Arch Dermatol Res* 2007; 299: 111–138.
40. National Institute for Health and Clinical Excellence (NICE). Psoriasis: the assessment and management of psoriasis. London (UK): National Institute for Health and Clinical Excellence (NICE); 2012 Oct. 61 p. (NICE clinical guideline; no. 153).
41. Meeuwis KA, et al. Genital psoriasis: a systematic literature review on this hidden skin disease. *Acta Derm Venereol* 2011; 91: 5–11.
42. Bissonnette R, Nigen S and Bolduc C. Efficacy and tolerability of topical tacrolimus ointment for the treatment of male genital psoriasis. *J Cutan Med Surg* 2008; 12: 230–234.
43. Vena GA, Micali G, Santoianni P, et al. Oral terbinafine in the treatment of multi-site seborrheic dermatitis: a multicenter, double-blind placebo-controlled study. *Int J Immunopath Pharmacol* 2005; 18: 745–753.
44. Zawar V, Kirloskar M and Chuh A. Fixed drug eruption – a sexually inducible reaction? *Int J STD AIDS* 2004; 15: 560–563.
45. Braun-Falco O, Plewig G and Wolff HH (eds) *Dermatology*. Berlin: Springer-Verlag, 1991, p.553.
46. Schellhammer PF, Jordan GH, Robey EL, et al. Premalignant lesions and nonsquamous malignancy of the penis and carcinoma of the scrotum. *Urol Clin North Am* 1992; 19: 131–142.
47. Wieland U, Jurk S, Weissenborn S, et al. Erythroplasia of Queyrat: co-infection with cutaneous carcinogenic human papillomavirus type 8 and genital papillomaviruses in a carcinoma in situ. *J Invest Dermatol* 2000; 115: 396–401.
48. Mikhail GR. Cancers, precancers and pseudocancers on the male genitalia: a review of clinical appearances, histopathology, and management. *J Dermatol Surg Oncol* 1980; 6: 1027.
49. Cox NH, Eedy DJ and Morton CA. Guidelines for management of Bowen's disease: 2006 update. *Br J Dermatol* 2007; 156: 11–21.
50. Goorney BP and Polori R. A case of Bowenoid papulosis of the penis successfully treated with topical imiquimod cream 5%. *Int J STD AIDS* 2004; 15: 833–835.
51. Peris K, Micantonio T, Fargnoli MC, et al. Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma. *J Am Acad Dermatol* 2006; 55: 324–327.
52. Axcróna K, Brennhovd B, Alfsen GC, et al. Photodynamic therapy with methyl aminolevulinate for atypia/carcinoma in situ of the penis. *Scand J Urol Nephrol* 2007; 21: 1–4.
53. Goette DK, Elgart M and De Villez RL. Erythroplasia of Queyrat: treatment with topically applied fluorouracil. *JAMA* 1975; 232: 934.
54. Sonnex TS, Ralfs IG, Delanza MP, et al. Treatment of Erythroplasia of Queyrat with liquid nitrogen cryosurgery. *Br J Dermatol* 1982; 106: 581–584.
55. Edwards S. Balanitis and balanoposthitis: a review. *Genitourin Med* 1996; 72: 155–159.

## Appendix I. Search strategy

Evidence for this guideline has been provided by undertaking a search for English language articles published up to June 2012 from the following sources: Medline/Pubmed and Embase, the Cochrane Library (including the Cochrane Database of Systematic Reviews, Database of Abstracts and Reviews of Effects and Cochrane Central Register of Controlled Trials), British Association for Sexual Health and HIV (BAS HH) and British Association of Dermatologists (BAD) guidelines (including the previous European guideline for the management of balanitis 2001, and the UK National guideline for the management of balanitis 2008, and guidelines). No other relevant guidelines were identified on Google or produced by the US Centres for Disease Control. A further search of the Cochrane databases and National Institute for Health and Clinical Excellence guidelines were undertaken up to December 2012. Search terms included 'balanitis,' 'balanoposthitis' and all the specific aetiologies as listed in the introduction. This guideline is based on the 2001 European guideline for the management of balanitis with reference to UK National guideline for the management of balanitis 2008.

## Appendix 2. Levels of evidence and grading of recommendations

### Levels of evidence

- Ia Evidence obtained from meta-analysis of randomised controlled trials.

- Ib Evidence obtained from at least one randomised controlled trial.
- IIa Evidence obtained from at least one well-designed study without randomisation.
- IIb Evidence obtained from at least one other type of well designed quasi-experimental study.
- III Evidence obtained from well-designed non-experimental descriptive studies such as comparative studies, correlation studies and case control studies.
- IV Evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities.

### Grading of recommendations

- A (Evidence levels Ia, Ib) Requires at least one randomised control trial as part of the body of literature of overall good quality and consistency addressing the specific recommendation.
- B (Evidence levels IIa, IIb, III) Requires availability of well-conducted clinical studies but no randomised clinical trials on the topic of recommendation.
- C (Evidence IV) Requires evidence from expert committee reports or opinions and/or clinical experience of respected authorities. Indicates absence of directly applicable studies of good quality.

### Appendix 3. Declaration of Interests

None

### Appendix 4. Composition of the editorial board

Dr Keith Radcliffe, UK – Editor-in-Chief  
 Dr Marco Cusini, Italy  
 Dr Gilbert Donders, Belgium  
 Prof Mikhail Gomberg, Russia  
 Dr Michel Janier, France  
 Dr Jorgen Skov Jensen, Denmark  
 Prof Harald Moi, Norway  
 Dr Raj Patel, UK  
 Prof Jonathan Ross, UK  
 Dr Jackie Sherrard, UK  
 Dr Magnus Unemo, Sweden  
 Dr Willem van der Meijden, Netherlands  
 Dr Simon Barton (UK) – UEMS representative, UK  
 Dr Lali Khotenashvili – WHO European Office representative, Georgia  
 Prof Mario Poljak – ESCMID representative, Slovenia  
 Prof George-Sorin Tiplica, – EADV representative, Romania  
 - EDF representative